Alterations in EGFR, as well as in other genes such as KRAS mutations or ALK translocations, are frequent in lung adenocarcinoma; all these changes have been involved in the activation of signaling pathways critical in lung tumorigenesis, such as MAPK and PI3K/AKT pathways [12–14]. Here, EGFR is linked to lung adenocarcinoma.